New Delhi[India], December 9 (ANI): In a major development related to COVID-19 vaccine, Subject Expert Committee (SEC) of Drugs Controller General of India (DCGI) has asked for more safety and efficacy data from Serum Institute of India (SII) and Bharat Biotech for their COVID-19 vaccines.

According to government sources, an SEC meeting was held on Wednesday to review the application submitted by the pharma majors for emergency use authorisation (EUA) for their vaccine candidates.

Also Read | Bihar: Assailants Loot Gold Worth Rs 14 Lakh in Broad Daylight From Shop in Darbhanga (Watch Video).

"Serum Institute of India has been asked for an updated safety data of phase 2 and 3 clinical trial in the country and immunogenicity data from the clinical trial in the United Kingdom and India. While considering the application of Bharat Biotech company, the SEC after detailed evaluation recommended that the pharma major should submit the safety and efficacy data from its ongoing phase 3 clinical trial in India for more analysis," a source said.

The application submitted by the Pfizer was not discussed at the SEC meeting as the company has requested for more time for giving its presentation, sources said. (ANI)

Also Read | Anti-Cow Slaughter Bill Passed by Karnataka Assembly Amid Opposition Parties Boycott and Walkout.

(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)